TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Drug discovery remains unevenly distributed worldwide. While many countries in the Global South carry a high burden of infectious, neglected, inflammatory, ...

Artificial intelligence (AI) can accelerate drug development, reduce costs, and improve treatment efficacy, but faces challenges like data quality and regulatory hurdles. Over 900 FDA-approved ...

Artificial intelligence and machine learning are being embedded in every aspect of the drug discovery and development process. In the preclinical stages, for example, companies are using advanced AI ...

Regina Barzilay is a School of Engineering Distinguished Professor of AI & Health in the department of computer science and the AI faculty lead at MIT Jameel Clinic. She develops machine learning ...

Big investments in artificial intelligence (AI) don’t guarantee big wins. This point was emphasized by Niven R. Narain, the president and CEO of BPGbio president and CEO Niven R. Narain, PhD, in an ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Modern Medical Research Laboratory. Scientific Lab, Drug Engineering Center Full of ...

New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...